Compare JHG & BLCO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | JHG | BLCO |
|---|---|---|
| Founded | 1934 | 1853 |
| Country | United Kingdom | Canada |
| Employees | N/A | N/A |
| Industry | Investment Managers | Ophthalmic Goods |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.8B | 6.0B |
| IPO Year | N/A | 2022 |
| Metric | JHG | BLCO |
|---|---|---|
| Price | $45.60 | $16.90 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 8 | 14 |
| Target Price | ★ $47.88 | $17.31 |
| AVG Volume (30 Days) | ★ 811.3K | 408.9K |
| Earning Date | 01-30-2026 | 10-29-2025 |
| Dividend Yield | ★ 3.52% | N/A |
| EPS Growth | ★ 33.81 | N/A |
| EPS | ★ 3.39 | N/A |
| Revenue | $2,663,300,000.00 | ★ $4,976,000,000.00 |
| Revenue This Year | $10.79 | $8.08 |
| Revenue Next Year | $6.90 | $5.77 |
| P/E Ratio | $13.42 | ★ N/A |
| Revenue Growth | ★ 14.14 | 6.23 |
| 52 Week Low | $28.26 | $10.45 |
| 52 Week High | $49.42 | $18.99 |
| Indicator | JHG | BLCO |
|---|---|---|
| Relative Strength Index (RSI) | 61.27 | 59.76 |
| Support Level | $45.22 | $16.39 |
| Resistance Level | $46.36 | $17.41 |
| Average True Range (ATR) | 0.80 | 0.44 |
| MACD | 0.23 | 0.04 |
| Stochastic Oscillator | 76.96 | 64.73 |
Janus Henderson Group provides investment management services to retail intermediary (50% of managed assets), self-directed (20%) and institutional (30%) clients. At the end of September 2025, active equities (52%), fixed-income (32%), balanced (12%) and alternative (4%) investment platforms constituted the company's $484 billion in assets under management. Janus Henderson sources most of its managed assets from clients in North America (67%), with customers from Europe, the Middle East, Africa, and Latin America (25%) and the Asia-Pacific region (8%) accounting for the remainder.
Bausch & Lomb is one of the largest vision care companies in the US. The firm was previously a subsidiary under parent company Bausch Health and it was spun off to become a public company in 2022. It operates in three segments: vision care, surgical, and ophthalmic pharmaceuticals. Vision care is composed of contact lenses, a market that B&L controls 10%, and ocular health products, which includes Biotrue and Lumify. Surgical includes a suite of intraocular lenses, equipment for cataract and vitreoretinal surgeries, as well as surgical instruments. Ophthalmic pharmaceuticals has a diverse lineup of products, including Xipere, Vyzulta, and Lotemax that treat different complications. With over 100 products, B&L has the largest portfolio of eye care prescriptions in the space.